StockData
Biodexa Pharmaceuticals Plc logo

Biodexa Pharmaceuticals Plc (BDRX) stock

BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 1/30
$2.14−0.10 (-4.46%)

Close on Nov 17, 2026Market cap $4.83MP/E –Yield –

Biodexa Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2023 it was £381.00K, down 45.5% from the year before. The highest annual figure on record is £1.94M in fiscal 2018.

Annual revenue

PeriodPeriod endValueChange
FY2023Dec 31, 2023£381.00K-45.5%
FY2022Dec 31, 2022£699.00K+20.9%
FY2021Dec 31, 2021£578.00K+68.5%
FY2020Dec 31, 2020£343.00K-49.1%
FY2019Dec 31, 2019£674.00K-65.2%
FY2018Dec 31, 2018£1.94M+96.0%
FY2017Dec 31, 2017£989.00K-25.2%
FY2016Dec 31, 2016£1.32M-3.8%
FY2015Dec 31, 2015£1.38M–

More Biodexa Pharmaceuticals figures

See a number that looks wrong?